NCT06885619 Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
| NCT ID | NCT06885619 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Anzhen Hospital |
| Condition | Left Ventricular Remodeling |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-05-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years and ≤80 years. 2. Definite diagnosis of STEMI according to ESC/ACC guidelines: * Chest pain lasting \>30 minutes, and * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block. 3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3). 4. First STEMI (no prior history of myocardial infarction). 5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%. 6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up. Exclusion Criteria: 1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo. 2. Severe comorbidities: * Prior HF (NYHA ≥II); * Severe CKD (eGFR \<30 mL/min/1.73m² or dialysis); * Severe liver disease (Child-Pugh B/C); * Active malignancy (life expectancy \<1 year); * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding). 3. Fibrinolysis-followed-by-PCI. 4. Primary PCI complications: * No-reflow/slow-flow (final TIMI \<2); * Cardiogenic shock or mechanical complication within 7 days; * In-hospital repeat revascularization. 5. Inability to complete 6-month follow-up. 6. Factors affecting blood sampling/exosome/immune/proteome assays: * Blood transfusion within 1 month; * Known hemolytic disorder; * Inadequate venous access. 7. Pregnancy or lactation.
Contact & Investigator
Xu Wang, Dr.
PRINCIPAL INVESTIGATOR
Beijing Anzhen hospital, Capital Mediacl University.
Frequently Asked Questions
Who can join the NCT06885619 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Left Ventricular Remodeling. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06885619 currently recruiting?
Yes, NCT06885619 is actively recruiting participants. Contact the research team at huaianwangxu@126.com for enrollment information.
Where is the NCT06885619 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06885619 clinical trial?
NCT06885619 is sponsored by Beijing Anzhen Hospital. The principal investigator is Xu Wang, Dr. at Beijing Anzhen hospital, Capital Mediacl University.. The trial plans to enroll 1,000 participants.